Harold Moses

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Infliximab for the treatment of CNS sarcoidosis

Jeffrey M. Gelfand, Michael Bradshaw, Barney J. Stern et al. · Neurology · 2017 · 183 citations · Full text

Diagnostic and therapeutic aspects of Hashimoto's encephalopathy

Inan Olmez, Harold Moses, Subramaniam Sriram et al. · Journal of the Neurological Sciences · 2013 · 159 citations

Neuropsychology, Neurological Disorder, Neuroanatomy +10

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 99 citations · Full text

Influenza A virus-associated acute necrotizing encephalopathy in the United States

Jörn-Hendrik Weitkamp, Michele Spring, TERRANCE BROGAN et al. · The Pediatric Infectious Disease Journal · 2004 · 72 citations

Virus Epidemiology, Neurological Disorder, Neurovirology +14